These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 14500401

  • 1. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini JC, Valmori D, Speiser D.
    Cancer Res; 2003 Sep 01; 63(17):5601-6. PubMed ID: 14500401
    [Abstract] [Full Text] [Related]

  • 2. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
    Valmori D, Dutoit V, Liénard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P.
    Cancer Res; 2000 Aug 15; 60(16):4499-506. PubMed ID: 10969798
    [Abstract] [Full Text] [Related]

  • 3. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D, Liénard D, Waanders G, Rimoldi D, Cerottini JC, Romero P.
    Cancer Res; 1997 Feb 15; 57(4):735-41. PubMed ID: 9044853
    [Abstract] [Full Text] [Related]

  • 4. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
    Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi D, Liénard D, Speiser D, Guillaume P, Batard P, Cerottini JC, Romero P, Valmori D.
    Cancer Res; 2001 Aug 01; 61(15):5850-6. PubMed ID: 11479225
    [Abstract] [Full Text] [Related]

  • 5. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D, Dutoit V, Ayyoub M, Rimoldi D, Guillaume P, Liénard D, Lejeune F, Cerottini JC, Romero P, Speiser DE.
    Cancer Immun; 2003 Oct 28; 3():15. PubMed ID: 14580186
    [Abstract] [Full Text] [Related]

  • 6. An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.
    Ayyoub M, Hesdorffer CS, Montes M, Merlo A, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Scanlan M, Old LJ, Valmori D.
    J Clin Invest; 2004 Apr 28; 113(8):1225-33. PubMed ID: 15085202
    [Abstract] [Full Text] [Related]

  • 7. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma.
    Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D, Valmori D, Romero P, Cerottini JC, Rammensee HG, Pfreundschuh M, Speiser D, Lévy F.
    J Immunol; 2002 Feb 15; 168(4):1717-22. PubMed ID: 11823502
    [Abstract] [Full Text] [Related]

  • 8. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D, Fonteneau JF, Lizana CM, Gervois N, Liénard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P.
    J Immunol; 1998 Feb 15; 160(4):1750-8. PubMed ID: 9469433
    [Abstract] [Full Text] [Related]

  • 9. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J.
    Cancer Res; 1997 Oct 15; 57(20):4570-7. PubMed ID: 9377571
    [Abstract] [Full Text] [Related]

  • 10. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
    Carrabba MG, Castelli C, Maeurer MJ, Squarcina P, Cova A, Pilla L, Renkvist N, Parmiani G, Rivoltini L.
    Cancer Res; 2003 Apr 01; 63(7):1560-7. PubMed ID: 12670905
    [Abstract] [Full Text] [Related]

  • 11. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis.
    Jenne L, Arrighi JF, Jonuleit H, Saurat JH, Hauser C.
    Cancer Res; 2000 Aug 15; 60(16):4446-52. PubMed ID: 10969791
    [Abstract] [Full Text] [Related]

  • 12. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A.
    Cancer Res; 2003 May 15; 63(10):2535-45. PubMed ID: 12750277
    [Abstract] [Full Text] [Related]

  • 13. An antigen-targeted approach to adoptive transfer therapy of cancer.
    Valmori D, Pittet MJ, Rimoldi D, Liénard D, Dunbar R, Cerundolo V, Lejeune F, Cerottini JC, Romero P.
    Cancer Res; 1999 May 01; 59(9):2167-73. PubMed ID: 10232604
    [Abstract] [Full Text] [Related]

  • 14. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
    Fujie T, Tanaka F, Mori M, Takesako K, Sugimachi K, Akiyoshi T.
    Clin Cancer Res; 1997 Dec 01; 3(12 Pt 1):2425-30. PubMed ID: 9815643
    [Abstract] [Full Text] [Related]

  • 15. Identification of a common HLA-A*0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy.
    He Y, Mao L, Lin Z, Deng Y, Tang Y, Jiang M, Li W, Jia Z, Wang J, Ni B, Wu Y.
    Mol Immunol; 2008 May 01; 45(9):2455-64. PubMed ID: 18295890
    [Abstract] [Full Text] [Related]

  • 16. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
    Stevens EJ, Jacknin L, Robbins PF, Kawakami Y, el Gamil M, Rosenberg SA, Yannelli JR.
    J Immunol; 1995 Jan 15; 154(2):762-71. PubMed ID: 7814882
    [Abstract] [Full Text] [Related]

  • 17. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires.
    Dietrich PY, Walker PR, Quiquerez AL, Perrin G, Dutoit V, Liénard D, Guillaume P, Cerottini JC, Romero P, Valmori D.
    Cancer Res; 2001 Mar 01; 61(5):2047-54. PubMed ID: 11280765
    [Abstract] [Full Text] [Related]

  • 18. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
    Valmori D, Gervois N, Rimoldi D, Fonteneau JF, Bonelo A, Liénard D, Rivoltini L, Jotereau F, Cerottini JC, Romero P.
    J Immunol; 1998 Dec 15; 161(12):6956-62. PubMed ID: 9862730
    [Abstract] [Full Text] [Related]

  • 19. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
    Shichijo S, Azuma K, Komatsu N, Ito M, Maeda Y, Ishihara Y, Itoh K.
    Clin Cancer Res; 2004 Sep 01; 10(17):5828-36. PubMed ID: 15355913
    [Abstract] [Full Text] [Related]

  • 20. Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2.
    Ayyoub M, Merlo A, Hesdorffer CS, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Chen YT, Old LJ, Stevanovic S, Valmori D.
    Clin Immunol; 2005 Jan 01; 114(1):70-8. PubMed ID: 15596411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.